Tramadol may induce psychic as well as physical dependence of opioid. Dependence and abuse, which includes drug-seeking behavior to unlawful actions to take the drug, aren’t limited to patients with prior history of opioid dependence. The risk in patients with substance abuse has been observed to be widespread. Tramadol is associated with tolerance development. It’s believed that if Tramadol is abruptly discontinued, withdrawal symptoms may occur. Tramadol is absorbed orally, as it can be administered in 50 to 100 mg tablets needed for pain relief every 4 to 6 hours (although not to exceed 400 mg/ day). Seizures normally occur in patients taking the recommended doses, but are even more likely at high doses combined with abuse of the Tramadol.

Dependence, along with tolerance and addiction to Tramadol, has been validated. The abrupt cessation from Tramadol has been likened with two types of withdrawal syndromes. One is customary of opioid drugs with flu-like symptoms, drug and restlessness. This type is encountered in about 90% cases of Tramadol withdrawal. The other withdrawal syndrome is encountered in about 10% cases of withdrawal from Tramadol. This is uncommon of opioids and more associated with extreme anxiety, confusion, panic attacks, paranoia, hallucinations, as well as tingling and numbness in the extremities.

Tramadol is normally well-tolerated as side-effects are generally transient. The side-effects reported include constipation, dizziness, drowsiness, nausea, vomiting and headache. Several cases declare that Tramadol is abused for its opiate adverse effects. Recently, there were an estimated 2,984 emergency room visits for Tramadol. Statistics show that approximately 1.3 million people have used Tramadol non-medically. It’s important to know that Tramadol is currently not controlled under the CSA (Controlled Substances Act).

Tramadol undergoes a particular hepatic metabolism through the cytochrome isozyme. Reduced doses may be used in hepatic and renal impairment. The most common adverse drug reactions are sweating, vomiting and nausea. Drowsiness is reported, but is less of an issue in comparison to other opioids. A common side-effect of most opioids, respiratory depression, is not clinically important in normal doses. By itself, Tramadol can diminish seizure threshold. When combined with inhibitors, tricyclic antidepressants-or in patients with epilepsy-the seizure threshold is further reduced. Seizures have been reported in humans receiving excessive single oral doses (normally 700 mg) or large intravenous doses (300 mg). Dosages of warfarin (coumadin) may need to be decreased for anti-coagulated patients to refrain from bleeding complications.

Tramadol can increase the risk of seizure in epileptic patients, namely with simultaneous use of tricyclic antidepressants (Elavil). No dosage reduction or adjustment is necessary in fit senor citizens 65-75 years of age. Patients over 75-years-old and those with kidney and liver dysfunction may need lower amounts of dosage. Tramadol may rarely be habit-forming; it should be avoided in patients with a history of opiate addiction or even hypersensitivity to opiate medicines. Moreover, mitosis from Tramadol may mask the extent, existence or intracranial pathology. Physicians and clinicians should maintain a high index of suspicion for unfavorable drug reaction when evaluating reworked mental status in patients receiving Tramadol.

This entry was posted on Monday, February 9th, 2009 at 1:21 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.